California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
CA insulin
Why it matters: More than 3.5 million Californians have diabetes, and insulin is a life-saving part of their disease ...
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...
The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj ... Both a 3-mL ...
In a landmark moment for Saudi Arabia’s healthcare sector, the Kingdom inaugurated its first local insulin manufacturing ...
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.
While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...